7 January 2026 - iECURE today announced that the US FDA has granted regenerative medicine advanced therapy designation to ECUR-506, the company’s investigational in vivo targeted gene insertion therapy for the treatment of neonatal onset ornithine transcarbamylase deficiency.

Awarded Innovation Passport under the United Kingdom’s relaunched Innovative Licensing and Access Pathway.

Read iECURE press release